Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Anika Therapeutics (ANIK) EPS (Weighted Average and Diluted) (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed EPS (Weighted Average and Diluted) for 16 consecutive years, with $0.12 as the latest value for Q4 2025.

  • Quarterly EPS (Weighted Average and Diluted) rose 170.59% to $0.12 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$0.65 through Dec 2025, down 10.17% year-over-year, with the annual reading at -$0.7 for FY2025, 16.67% down from the prior year.
  • EPS (Weighted Average and Diluted) for Q4 2025 was $0.12 at Anika Therapeutics, up from -$0.16 in the prior quarter.
  • The five-year high for EPS (Weighted Average and Diluted) was $1.11 in Q4 2023, with the low at -$0.71 in Q1 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.05, with a median of -$0.17 recorded in 2024.
  • Peak annual rise in EPS (Weighted Average and Diluted) hit 307.5% in 2022, while the deepest fall reached 825.0% in 2022.
  • Over 5 years, EPS (Weighted Average and Diluted) stood at -$0.4 in 2021, then surged by 307.5% to $0.83 in 2022, then surged by 33.73% to $1.11 in 2023, then plummeted by 115.32% to -$0.17 in 2024, then soared by 170.59% to $0.12 in 2025.
  • According to Business Quant data, EPS (Weighted Average and Diluted) over the past three periods came in at $0.12, -$0.16, and -$0.33 for Q4 2025, Q3 2025, and Q2 2025 respectively.